Floatz logo

Irinotecan

Metastatic Urethral Urothelial Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Metastatic Urethral Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Epirubicin
Alliance for Clinical Trials in Oncology
Phase 3BB
Cyclophosphamide
Alliance for Clinical Trials in Oncology
Phase 3BB
Atezolizumab
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 12 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →